OPYT EFFEKTIVNOY GORMONOKhIMIOTERAPII BOL'NOGO RAKOM PREDSTATEL'NOY ZhELEZY STADII T4N1M0
- Authors: Selivanov S.P.1, Barysheva E.V.1, Kovalik T.A.1, Isaeva S.N.1, Petlin A.V.1
-
Affiliations:
- Issue: No 3 (2012)
- Pages: 47-50
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/279477
- ID: 279477
Cite item
Open Access
Access granted
Abstract
Full Text
References
- Jemal A., Bray F., Center M. M. et al. Forman global cancer statistics. Cancer J. Clin. 2011; 61 (2): 69—90.
- Andriole G. L., Crawford E. D., Grubb R. L. et al. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 2009; 360: 1310—1319.
- Parkin D. M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. Cancer J. Clin. 2005; 55: 74—108.
- Khan M., Partin A. Management of high-risk populations with locally advanced prostate cancer. Oncologist 2003; 8 (3): 259—269.
- Mohler J., Bahnson R. R., Boston B. et al. Prostate cancer. Prostate cancer clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 2010; 8 (2): 162—200.
- Heidenreich A., Aus G., Bolla M. et al. EAU guidelines on prostate cancer. Eur. Urol. 2007; 53 (1): 68—80.
- Loriot Y., Massard C., Gross-Goupil M. et al. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann. Oncol. 2009; 20: 703—708.
- Oh W. K., Tay M., Huang J. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Cancer 2007; 109 (3): 477—486.
- Ross R. W., Beer T. M., Jacobus S.A., Phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer 2008; 112 (3): 521—526.
- Ryan C. J., Eisenberger M. Chemotherapy for hormone-refractory prostate cancer: now it’s a question of "When?". J. Clin. Oncol. 2005; 23 (32): 8242—8246.
- Dreicer R., Klein E. A. Preliminary observations of single-agent docetaxel as neoadjuvant therapy for locally advanced prostate cancer. Semin. Oncol. 2001; 28: 45—48.
- Gleave M., Kelly W. K. High-risk localized prostate cancer: A case for early chemotherapy. J. Clin. Oncol. 2005; 23: 8186—8191.
- Oh W. K., George D. J., Kaufman D. S. et al. Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report. Semin. Oncol. 2001; 28: 40—44.
- Sternberg C. N. Overview of international collaborative group prostate cancer trials. Crit. Rev. Oncol. Hematol. 2002; 43: 153—158.
Supplementary files
